Lilly’s mirikizumab meets primary endpoints in Phase 3 Crohn’s disease trial
In the mirikizumab arm of the study, 45.4% of patients achieved clinical response at week 12 and clinical…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Oct 23
In the mirikizumab arm of the study, 45.4% of patients achieved clinical response at week 12 and clinical…
13 Oct 23
In the trial, Rinvoq showed a percent change from baseline in the Facial Vitiligo Area Scoring Index at…
13 Oct 23
Under the terms of this agreement, Almirall will gain a license to utilize EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig)…
13 Oct 23
Under the terms of the agreement, MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and…
12 Oct 23
For the second cell therapy of BMS, Cellares will optimise, automate, and tech-transfer the additional CAR-T cell therapy…
12 Oct 23
The microbiome mapping technology provider has acquired the assets to scale the discovery, development, and production of microbiome-based…
12 Oct 23
Zynerba Pharmaceuticals stands at the forefront of producing pharmaceutical-grade transdermal cannabinoid therapies specifically tailored for orphan neuropsychiatric disorders
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
12 Oct 23
Under this agreement, IMIDomics has licensed cutting-edge technology and expertise from UB to advance research aimed at understanding…
12 Oct 23
PacBio WGS Variant Pipeline Will Bring Standardization to PacBio HiFi Data Analysis
11 Oct 23
The platform is said to detect and optimise new, customisable LNPs to safely and effectively deliver RNA and…